Results 21 to 30 of about 54,679 (264)

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

World Journal of Surgical Oncology, 2020
Background Currently, nivolumab and ipilimumab are the most widely used immune checkpoint inhibitors. We performed a meta-analysis to evaluate the efficacy and treatment-related adverse events (TRAEs) of nivolumab plus ipilimumab therapy in cancer ...
Jingjie Chen, Shengnan Li, Qigu Yao, Nannan Du, Xiaojun Fu, Yuanmei Lou, Mengru Wang, Feiyan Mao, Danyi Mao, Parikshit Asutosh Khadaroo, Yingying Tang   +10 more
doaj   +1 more source

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

New England Journal of Medicine, 2018
BACKGROUND Nivolumab plus ipilimumab produced objective responses in patients with advanced renal‐cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear‐cell advanced renal ...
R. Motzer, N. Tannir, D. McDermott, O. A. Frontera, B. Melichar, T. Choueiri, E. Plimack, P. Barthélémy, C. Porta, S. George, T. Powles, F. Donskov, V. Neiman, C. Kollmannsberger, P. Salman, H. Gurney, R. Hawkins, A. Ravaud, M. Grimm, S. Bracarda, C. Barrios, Y. Tomita, D. Castellano, B. Rini, Allen C. Chen, Sabeen Mekan, B. McHenry, M. Wind-Rotolo, J. Doan, Padmanee Sharma, H. Hammers, B. Escudier   +31 more
semanticscholar   +1 more source

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

The Lancet, 2021
BACKGROUND Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy regimens that have moderate survival benefit with poor outcomes. Nivolumab plus ipilimumab has shown clinical benefit in other tumour types,
P. Baas, A. Scherpereel, A. Nowak, N. Fujimoto, S. Peters, A. Tsao, A. Mansfield, S. Popat, T. Jahan, S. Antonia, Y. Oulkhouir, Y. Bautista, R. Cornelissen, L. Greillier, F. Grossi, D. Kowalski, J. Rodríguez-Cid, P. Aanur, A. Oukessou, C. Baudelet, G. Zalcman   +20 more
semanticscholar   +1 more source

Ipilimumab [PDF]

Drugs in R&D, 2010
Ipilimumab (BMS734016; MDX 101; MDX-010; MDX-CTLA-4; MDX-CTLA4) is an anti-CTLA-4 monoclonal antibody, which is in development by Medarex Inc. and Bristol-Myers Squibb as treatment for malignant melanoma, prostate cancer, lymphoma, and lung cancer. It is currently in phase III development for the melanoma and prostate cancer indications, and phase II ...
openaire   +2 more sources

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

Clinical and Translational Science, 2023
This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC).
Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Yan Feng, Ling Gao, Urvi Aras   +9 more
doaj   +1 more source

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

New England Journal of Medicine, 2019
BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial. METHODS We randomly
J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. Grob, P. Rutkowski, C. Lao, C. Cowey, D. Schadendorf, J. Wagstaff, R. Dummer, P. Ferrucci, M. Smylie, D. Hogg, A. Hill, I. Márquez-Rodas, J. Haanen, M. Guidoboni, M. Maio, P. Schöffski, M. Carlino, C. Lebbé, G. McArthur, P. Ascierto, G. Daniels, G. Long, L. Bastholt, J. Rizzo, Á. Balogh, A. Moshyk, F. Hodi, J. Wolchok   +30 more
semanticscholar   +1 more source

Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels

Frontiers in Oncology, 2014
Stage IV metastatic melanoma patients historically have a poor prognosis with 5-10% 5-year survival. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA4), is one of the first treatments to provide beneficial durable ...
Anna M. Leung, Agnes Fermin Lee, Junko eOzao-Choy, Romela Irene Ramos, Omid eHamid, Steven J. O'Day, Myung eShin-Sim, Donald L. Morton, Mark B. Faries, Peter A. Sieling, Delphine J Lee   +10 more
doaj   +1 more source

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

New England Journal of Medicine, 2010
BACKGROUND An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab — which blocks cytotoxic T-lymphocyte–associated antigen 4 to potentiate an antitumor T-cell response ...
F. Hodi, S. O'Day, D. McDermott, R. Weber, J. Sosman, J. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. Hassel, W. Akerley, A. van den Eertwegh, J. Lutzky, P. Lorigan, Julia Vaubel, G. Linette, D. Hogg, C. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, Joseph I. Clark, J. Wolchok, J. Weber, Jason Tian, M. Yellin, G. Nichol, A. Hoos, W. Urba   +28 more
semanticscholar   +1 more source

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

Journal for ImmunoTherapy of Cancer, 2022
Background Acral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1 ...
Bart Neyns, Lisa Zimmer, Caroline Robert, Celeste Lebbe, Olivier Michielin, Omid Hamid, Anne Zaremba, Oliver Klein, Ruth Plummer, Joanna Mangana, Paolo A Ascierto, Katharina C Kähler, Georgina V Long, Ryan Sullivan, Grant A McArthur, Michael Weichenthal, Egle Ramelyte, Meghan J Mooradian, Douglas B Johnson, Alexander Shoushtari, Christian U Blank, Judith M Versluis, Prachi Bhave, Claudia Trojanello, Lu Si, Inderjit Mehmi, Tasnia Ahmed, Alexander M Menzies, Adnan Khattak, Severine Roy, Matteo S Carlino, Paul C Lorigan, Clara Allayous, Rachel Roberts-Thomson, Florentia Dimitriou, Kathleen Batty, Thierry Lesimple, Serigne N Lo, Alexandre Wicky, Richard Heywood, Lena Tran, Anna Stansfeld, Julia K Schwarze, Andrea Maurichi, Hui-Ling Yeoh, Mario Santinami, Andrew M Haydon   +46 more
doaj   +1 more source

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

Health and Quality of Life Outcomes, 2012
Background In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients.
Revicki Dennis A, van den Eertwegh Alfons JM, Lorigan Paul, Lebbe Celeste, Linette Gerald, Ottensmeier Christian H, Safikhani Shima, Messina Marianne, Hoos Axel, Wagner Samuel, Kotapati Srividya   +10 more
doaj   +1 more source